AstraZeneca Pharma India Ltd has received approval from the Central Drugs Standard Control Organization (CDSCO) to market its cancer drug Durvalumab (brand name Imfinzi) for an additional indication in India. The regulatory clearance allows the company to import and distribute the infusion in strengths of 120 mg/2.4 mL and 500 mg/10 mL.
The approval marks a significant step in expanding treatment options for cancer patients in the country. Imfinzi, an immunotherapy drug, is used in the treatment of certain types of cancers and works by enhancing the body’s immune response against cancer cells.
In a regulatory filing on February 10, 2026, AstraZeneca said the latest nod from India’s drug regulator paves the way for broader clinical use of the therapy. The development strengthens AstraZeneca’s oncology portfolio in India and supports improved access to advanced cancer treatments.
